Abstract
Purpose
Androgen receptor (AR) is a recognized immunohistochemical marker of prostate cancer. However, the sensitivity and specificity of AR for prostate cancer in the setting of other genitourinary neoplasms has not been rigorously studied.
Methods
We employed tissue microarrays containing prostate carcinomas, urothelial carcinomas, renal cell carcinomas, and testicular neoplasms. Slides were stained immunohistochemically for AR.
Results
Androgen receptor was positive in 95 % of prostate carcinomas (n = 230), but 19 % of invasive urothelial carcinomas of the bladder (n = 190) and 33 % of non-invasive bladder urothelial carcinomas were also AR positive (N = 107). Furthermore, 16 % of renal pelvis urothelial carcinomas (n = 43) were positive. Of primary renal cell carcinomas, 19 % were AR positive (n = 307). From a metastatic renal cell carcinoma cohort, 28 % of metastases were AR positive (N = 126). Six percent of non-teratomatous testicular germ cell tumors stained for AR (n = 103).
Conclusions
Our data show that the sensitivity of AR immunohistochemistry for prostate cancer is 94.8 %. However, the specificity of AR is only 81.4 %, among our cohort of invasive genitourinary tumors. Thus, we find the specificity of AR suboptimal, yet AR may remain useful as a component of an immunostain panel.
Similar content being viewed by others
References
Downes MR, Torlakovic EE, Aldaoud N, Zlotta AR, Evans AJ, van der Kwast TH (2013) Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma. J Clin Pathol 66:779–786. doi:10.1136/jclinpath-2013-201586
Pertschuk LP, Schaeffer H, Feldman JG, Macchia RJ, Kim YD, Eisenberg K, Braithwaite LV, Axiotis CA, Prins G, Green GL (1995) Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab Invest 73:302–305
Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C, Loda M (1997) Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 10:839–845
Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Bostwick DG (1999) Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol 161:1229–1232
Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL (2001) Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 61:423–427
Ricciardelli C, Jackson MW, Choong CS, Stahl J, Marshall VR, Horsfall DJ, Tilley WD (2008) Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 68:830–838. doi:10.1002/pros.20747
Lévesque M-H, El-Alfy M, Cusan L, Labrie F (2009) Androgen receptor as a potential sign of prostate metastasis. Prostate 69:1704–1711
Fleischmann A, Rocha C, Schobinger S, Seiler R, Wiese B, Thalmann GN (2011) Androgen receptors are differentially expressed in gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. 71:453–460. doi:10.1002/pros.21259
Birtle AJ, Freeman A, Munson P (1994) The androgen receptor revisited in urothelial carcicnoma. Histopathology 45:98–99
Boorjian S, Ugras S, Mongan N, Gudas LJ, You X, Tickoo SK, Scherr DS (2004) Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64:383–388
Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ, Tindall DJ (2009) Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer 16:123–137
Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, van Rhijn BWG, Bostrom P, Yao J, Miyaoto H, Jewett M, Fleshner N, Messing E, Zlotta AR (2010) Loss of androgen receptor expression is not associated with pathological stage, grade, gender, or outcome in bladder cancer: a large multi-institutional study. BJU Int 108:24–30
Rau K-M, Chen Y-J, Sun M-T, Kang H-Y (2011) Prognostic effects and regulation of Activin A, Mapsin, and the androgen receptor in upper urinary tract urothelial carcinoma. Anticancer Res 31:1713–1720
Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, Gudas LJ, Mongan NP (2011) Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 931–944. doi:10.1002/mc.20758
Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M, Sertcelik N (2011) Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 29:43–51. doi:10.1016/j.urolonc.2009.01.033
Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S (2012) Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109:1716–1726. doi:10.1111/j.1464-410X.2011.10706.x
Shyr C-R, Chen C-C, Hseih T-F, Chang C-H, Ma W-L, Yeh S, Messing E, Li T-H, Li F-Y, Chang C (2013) The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells. Endocrine 43:191–199
Noh SJ, Kang J, Kim KM, Bae JS, Park HS, Moon WS, Chung MJ, Lee H, Lee DG, Jang KY (2013) Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients. Pathology 45:574–580
Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R (2004) Steroid hormone receptor expression in renal cell caracinoma: an immunohistochemical analysis of 182 tumors. J Urol 171:611–614
Zhu G, Liang L, Li L, Dang Q, Song W, Yeh S, He D, Chang C (2014) The expression and evaluation of androgen receptor in human renal cell carcinoma. Urology 83:510.e19–510.e24. doi:10.1016/j.urology.2013.10.022
Rajpert-De Meyts E, Skakkebaek NE (1992) Immunohistochemical identification of androgen receptors in germ cell neoplasia. J Endocrinol 135(2):R1–R4
Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, Marinelli RJ, Presti JC Jr, van de Rijn M, Brooks JD (2007) Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 31:673–680
Howitt BE, Brooks JD, Jones S, Higgins JPT (2013) Identification and characterization of 2 testicular germ cell markers, Glut3 and CyclinA2. Appl Immunohistochem Mol Morphol 21:401–407
Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI (2007) Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 31:1246–1255
Brimo F, Epstein JI (2012) Immunohistochemical pitfalls in prostate pathology. Hum Pathol 43:313–324. doi:10.1016/j.humpath.2011.11.005
Epstein JI, Egevad L, Humphrey PA, Montironi R (2014) Best practices recommendations in the application of immunohistochemistry in the prostate: report from the international society of urologic pathology consensus conference. Am J Surg Pathol 38(8):6–19. doi:10.1097/PAS.0000000000000238
Acknowledgments
The authors wish to acknowledge the expert technical assistance of Linh Matsumura with AR immunostaining. A subset of this data was presented in abstract form at the USCAP annual meeting, March 2013, Baltimore, MD.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Williams, E.M., Higgins, J.P., Sangoi, A.R. et al. Androgen receptor immunohistochemistry in genitourinary neoplasms. Int Urol Nephrol 47, 81–85 (2015). https://doi.org/10.1007/s11255-014-0834-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-014-0834-7